INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION
ASERBINE (cream)
ASERBINE S (solution)

ASERBINE
Desloughing Agents

SCHEDULING STATUS:
Not scheduled.

PROPRIETARY NAMES
(and dosage form):

ASERBINE (cream)
ASERBINE S (solution)

COMPOSITION:

	Aserbine	Aserbine S
	%	%
Malic acid	0,375	2,25
Benzoic acid	0,025	0,15
Salicylic acid	0,006	0,0375
Propylene glycol	1,75	40,0
Methyl hydroxybenzoate	0,005
Propyl hydroxybenzoate	0,010

PHARMACOLOGICAL CLASSIFICATION:
A.14 Treatment of wounds.

PHARMACOLOGICAL ACTION:
A study of the effect of varying pH levels on the swelling of proteins has shown that the degree of swelling is related to the orientation and stability of the different protein structures.
The pH of Aserbine is such that, when applied to a wound it causes maximum differential swelling between the living protein of healthy tissues and the less well orientated dead proteins of slough, leading to separation of the dead tissue (desloughing) and proliferation of granulation tissue.

INDICATIONS:
Aserbine is indicated whenever the presence of slough delays healing in:
Burns
Chronic Skin Ulcers
        Varicose ulcers and other benign indolent ulcers: Trophic ulcers including pressure sores.
Traumatic injury
        Crushed limb injuries: Multiple lesions.
Also indicated in surgical procedures where slough may be a problem.
Preparation of skin grafting: Mastectomies: Amputations: Post-surgical incisions.

ADVANTAGES:
When healing is delayed by the presence of slough and debris, Aserbine will deslough and clear the wound surface.
Aserbine allows uninterrupted normal healing to proceed, improves granulation tissue and stimulates the growing epithelium.
Aserbine has anti-bacterial properties to guard against wound infections.
Aserbine does not affect living tissue.
When dressings are used with Aserbine they are non-adherent and may be removed easily and painlessly.
No toxic or untoward side-effects attributable to the use of Aserbine have been observed.

CONTRA-INDICATIONS:
There is no documented experience on the use of Aserbine in human pregnancy or lactation. Careful consideration should therefore be given before its use during the first trimester of pregnancy.

DIRECTIONS FOR USE:
Aserbine has been shown to be compatible with most dressing techniques; it is presented as a cream and as a solution.
Aserbine cream may be applied either directly to the affected area or on gauze. Twice daily liberal applications have been found to produce the best results. Fresh applications may be made if necessary at more frequent intervals.
Aserbine S should be applied as a wet dressing which should be kept constantly moist.
Aserbine S may be used as a cleansing agent to remove debris and coagulum from wounds. Before each new application of Aserbine cream, Aserbine S may be used to remove loose slough and cream from the previous application.
In a few cases it has been found necessary to keep Aserbine away from the hypersensitive epithelium on the periphery of the wound.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
No toxic effects attributable to the use of Aserbine have been observed in most patients. Mild pyrexia, partially due to the absorption of protein products of slough breakdown from the wound, has been reported when severely burned patients were treated with Aserbine.
Irritation of the hypersensitive skin surrounding the wound may occur in some patients; occasionally a mild urticarial rash has been seen for a small distance round the treated area. The discomfort was slight and readily controlled by antihistamines, locally and systemically.
Aserbine has a low pH and care should be taken to avoid contact with the eyes.

IDENTIFICATION:

Aserbine	–A white cream.
Aserbine S	– A clear, colourless solution with an odour of rosewater.

PRESENTATION:
Aserbine is available in tubes containing 50g or polythene jars containing 500g.
Aserbine S is available in polyethylene bottles containing 500 mL.

STORAGE INSTRUCTIONS:
Store below 25°C.
KEEP OUT OF REACH OF CHILDREN.

REFERENCE NUMBERS:
Aserbine        H.1007 (Act 101/1965)
Aserbine S        H.1006 (Act 101/1965)

NAME AND BUSINESS ADDRESS OF THE APPLICANT:
SmithKline Beecham Pharmaceuticals (Pty) Ltd.
6 Carey Street,
Wynberg Ext. 6,
Johannesburg 2090.

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
21.02.1990.

Aserbine and the SB logo are trademarks.

                P0708
SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996,1997,1998